Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Antiangiogenic therapy targeting the vascular endothelial growth factor (VEGF) pathway is crucial for cancer treatment.
• Acquired resistance to antiangiogenic drugs remains a significant clinical challenge, limiting treatment efficacy.
• Understanding the molecular mechanisms underlying adaptive resistance is essential for developing effective therapeutic strategies.

Purpose of the Study:

• To identify novel molecular targets involved in adaptive resistance to antiangiogenic therapy.
• To investigate the role of CD5L (CD5 antigen-like precursor) in the development of resistance.
• To evaluate the therapeutic potential of targeting CD5L in preclinical cancer models.

Main Methods:

• Gene expression analysis in response to antiangiogenic treatment.
• In vitro and in vivo studies using RNA-aptamers and monoclonal antibodies against CD5L.
• Assessment of tumor growth, angiogenesis, and patient survival data.

Main Results:

• CD5L was identified as a key gene upregulated during adaptive resistance to antiangiogenic therapy.
• Targeting CD5L with specific agents effectively inhibited pro-angiogenic effects and tumor progression.
• Elevated vascular CD5L expression in cancer patients correlated with bevacizumab resistance and poorer survival.

Conclusions:

• CD5L plays a critical role in adaptive resistance to antiangiogenic therapy.
• Targeting CD5L represents a promising therapeutic strategy to overcome resistance and improve patient outcomes.
• CD5L inhibition may hold significant clinical utility in combination with existing antiangiogenic treatments.